Immunogen Inc. Message Board
-
7 is God's number, a good omen, 888 is next!
-
Better seek to partner with, or acquire better technology and stronger partners like IMGN, SGEN, or ECYT because it's obvoius PFE does not know ADC.
-
Reg"expert" seems desperate today, are you the same poster as the tradingexpert on the ACAD MB, who has been talking about shorting the stock since $5 (now $14)?
-
could be off-market, or on an exchange that your broker does not use. I have found Scottrade's OptionsFirst to be an excellent trading platform. I get very good fills, good prices, I often get price improvement and very low costs, I get a volume discount, but I won't be using it on any more ARNA calls since they always expire worthless.
Keep up the good work on the social media angle, we need all hands on deck to beat these criminal shorts. You can bet shorts will try to counder with an anti-Belviq page. They will stop at nothing to win at the expense of longs. -
How about Linked-in, is there a page there I can like?
-
I would take 1/10th of a share of REGN, that company is well managed and hugely successful. Unfortunately, REGN has so many in-house opportunities that they don't need to acquire. Very interesting company, I wish I had done more DD on them when they were $50 not that long ago. Even at this high price, the PE is not unreasonable. Looks like it wants to correct, so maybe it will be available at a lower price soon.
-
the drug may also help in other indications, this looks huge IMO and unfortunately I do not own the stock.
-
They need to be cutting the burn rate now to conserve cash. They also need to articulate their strategy. Silence is not a strategy!
-
Good catch on the insider activity, I missed this. On the one hand, there was some insider selling in ACAD in the $8+ range not long ago and it's $14+ today. On the other hand, I always worry when a CFO sells stock. Maybe TSRX will sell some stock in the not too distant future unless they find a deep pocketed partner. As far as the distributes shares, I would expect most of them to be sold, hence the lack of sustainable upward movement for now. TSRX might be stuck in a trading range until the shares are sold. All IMO, not advice, I am long.
-
on the + side, I am making good money trading IMGN, on the - side, I have a bunch of long, non-trading shares that are not doing much and trading takes time and effort. If I had only allocated more in ACAD I would be playing a lot more golf, it's up 7x+ in under a year, what a stock! Not that I am complaining for any of these Blessings, well maybe AVEO #$%$!
- Reply to
Spencer Stops Bashing - Writes a Gem _ _ _Turning Point ?
by neonfreon2007 •May 20, 2013 8:34 AMthe stock was trading at $2.00 or less not all that long before the acquisition if I recall correctly. HGSI management had plenty of time to succeed, they started out well, did some very interesting research, then let spending get out of control. Anyway, we are on the same side, hoping for an ARNA win before we grow old and die and not big fans of Spencer the wannabe biotech "analyst".
-
I must have data feed issues, this almost never happens. I did have 3000 trading shares called away, so maybe that explains it. I would rather have a price gain to $20+ this year and $30 next year and no buy out assuming the pipeline progresses and Kadcyla sales are strong. A happy Monday, ACAD is a monster stock.
- Reply to
Spencer Stops Bashing - Writes a Gem _ _ _Turning Point ?
by neonfreon2007 •May 20, 2013 8:34 AMwell, GSK paid up big time for HGSI, so you post seems to support his point. My point is that it's a known, known. Agree with you point about NOL not being a driver, I believe the acquired company has to generate revenue against which to use the NOL. I am not a tax law expert, but I am fairly certain company A (acquirer/strong co) can't just buy company B (loser/NOL co) and use company B's NOL against revenue/income produced by company A products.
-
yes, this is a terrible stock, you should keep shorting it. I hate stocks that go from $2 to 14+, too much wealth creation for longs :-)
- Reply to
Spencer Stops Bashing - Writes a Gem _ _ _Turning Point ?
by neonfreon2007 •May 20, 2013 8:34 AMhow does this now make him an expert in biotech investing/trading, by stating the obvious? Do you think shorts and institutional investors are unaware. This may have been a revelation to you, but not to professional investors. I could care less what Spencer writes and I find the timing interesting, one day after options expire worthless.
-
I have been selling 20-30 puts per month all year before the big jump from 9 to 13, so that motsly paid for the covered call loss.
-
Maybe I should change my MB name to tradingexpert...After multiple insiders sold stock in the $8's I sold the May $9 call thinking the stock would be dead for awhile. I sold it for about .35 and bought is back today on the last day for $4.04. Why, I did not want to pay tax on my large gain at the ST, marginal tax rate, so I moved out and up to the Dec 15 call giving the stock a little more room to run and cushining the blow and cost by $1.5. That was a good lesson, don't sell calls for peanuts. It's not the first time I have learned that lesson. It's funny, I lost more on the calls than I originally paid for the stock, so now my cost basis is around $6.5, but now I have a ST loss to use against other ST gains and any sale after Dec will be at the LT capital gains rate.
-
I seriously doubt IMGN would be trading around $16 if any info had leaked about a sale of the company. Maybe you own some May calls? If we see a rapid move back to $18, some large option and stock volume, I would entertain that thought.
-
I will make a point to visit the ASCO booth and see if I can learn what is happening at the company, hopefully some restructuring to cut the cash burn!
-
If the option criminals want to rig the game, I will not give them any more of my $. Fool me once...